Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM.
O⁶-methylguanine DNA-methyltransferase (MGMT) promoter methylation has been identified as a potential prognostic marker for glioblastoma patients. The relationship between the exact site of promoter methylation and its effect on gene silencing, and the patient's subsequent response to therapy, is still being defined. The aim of this study was to comprehensively characterize cytosine-guanine (CpG) dinucleotide methylation across the entire MGMT promoter and to correlate individual CpG site methylation patterns to mRNA expression, protein expression, and progression-free survival. To best identify the specific MGMT promoter region most predictive of gene silencing and response to therapy, we determined the methylation status of all 97 CpG sites in the MGMT promoter in tumor samples from 70 GBM patients using quantitative bisulfite sequencing. We next identified the CpG site specific and regional methylation patterns most predictive of gene silencing and improved progression-free survival. Using this data, we propose a new classification scheme utilizing methylation data from across the entire promoter and show that an analysis based on this approach, which we call 3R classification, is predictive of progression-free survival (HR  = 5.23, 95% CI [2.089-13.097], p<0.0001). To adapt this approach to the clinical setting, we used a methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) test based on the 3R classification and show that this test is both feasible in the clinical setting and predictive of progression free survival (HR  = 3.076, 95% CI [1.301-7.27], p = 0.007). We discuss the potential advantages of a test based on this promoter-wide analysis and compare it to the commonly used methylation-specific PCR test. Further prospective validation of these two methods in a large independent patient cohort will be needed to confirm the added value of promoter wide analysis of MGMT methylation in the clinical setting.
The Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, Washington, United States of America.
Nameeta
N
Shah
Biaoyang
B
Lin
Zita
Z
Sibenaller
Timothy
T
Ryken
Hwahyung
H
Lee
Jae-Geun
JG
Yoon
Steven
S
Rostad
Greg
G
Foltz
D001483:Base Sequence; D018899:CpG Islands; D019175:DNA Methylation / Q000235:genetics*; D015254:DNA Modification Methylases / Q000096:biosynthesis / Q000235:genetics*; D045643:DNA Repair Enzymes / Q000096:biosynthesis / Q000235:genetics*; D018572:Disease-Free Survival; D020868:Gene Silencing; D005909:Glioblastoma / Q000201:enzymology / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D006801:Humans; D011379:Prognosis; D011401:Promoter Regions, Genetic / Q000235:genetics*; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000096:biosynthesis / Q000235:genetics*
D025521:Tumor Suppressor Proteins; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes
J Neurooncol. 2007 Jun;83(2):173-9
17219056
Neurotherapeutics. 2009 Jul;6(3):478-86
19560738
Clin Cancer Res. 2007 May 1;13(9):2606-13
17473190
Mol Cancer Ther. 2006 Oct;5(10):2531-9
17041097
Neuro Oncol. 2009 Aug;11(4):348-56
19224763
J Clin Oncol. 2009 Mar 10;27(8):1275-9
19188675
J Mol Diagn. 2007 Jul;9(3):368-81
17591937
Mol Cancer. 2007 Jun 05;6:36
17547775
Clin Cancer Res. 2009 Nov 1;15(21):6683-93
19861461
Int J Oncol. 2008 Sep;33(3):469-75
18695875
Nat Rev Neurol. 2010 Jan;6(1):39-51
19997073
Cancer Res. 2007 Jan 15;67(2):580-4
17234766
J Neurooncol. 2009 Mar;92(1):23-31
19011762
N Engl J Med. 1980 Dec 4;303(23):1323-9
7001230
Lab Invest. 2007 Oct;87(10):1055-65
17700563
J Mol Diagn. 2008 Jul;10(4):332-7
18556773
Acta Neuropathol. 2008 Feb;115(2):249-59
17965865
Clin Cancer Res. 2004 Mar 15;10(6):1871-4
15041700
N Engl J Med. 2005 Mar 10;352(10):997-1003
15758010
Cancer Genomics Proteomics. 2009 Jul-Aug;6(4):219-27
19656999
Lancet Oncol. 2009 May;10(5):459-66
19269895
Oncogene. 2003 Dec 4;22(55):8835-44
14647440
Biotechniques. 2003 Feb;34(2):374-8
12613259
Neurosurgery. 2009 Nov;65(5):866-75; discussion 875
19834398
Lab Invest. 2007 Apr;87(4):392-7
17260000
J Neurooncol. 2008 Mar;87(1):71-8
18004504
Cancer Res. 1996 Feb 15;56(4):783-8
8631014
Genome Res. 1998 Mar;8(3):186-94
9521922
Neuro Oncol. 2010 Mar;12(3):274-82
20167815
Genome Res. 2002 Jun;12(6):996-1006
12045153
J Biol Chem. 1996 Jun 7;271(23):13916-24
8662860
Brain Pathol. 2008 Oct;18(4):520-32
18400046
J Mol Biol. 1987 Jul 20;196(2):261-82
3656447
Genome Res. 1998 Mar;8(3):175-85
9521921
Mol Cell Biol. 1991 Sep;11(9):4660-8
1875945
Bioinformatics. 2005 Nov 1;21(21):4067-8
16141249
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):670-6
19836157
Int J Cancer. 2007 Dec 1;121(11):2458-64
17691113
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Oncogene. 2007 Sep 13;26(42):6229-37
17384671